MHC class I-restricted human melanoma epitope MART-127–35 specific TCR-engineered
CD4+ CD25− T cells synthesize Th1 type cytokines and exhibit cytolytic effector function …

Background Adoptive cell transfer (ACT) is a promising cancer immunotherapeutic strategy
that remains ineffective for a large subset of patients. ACT with memory CD8+ T cells (T …

Background Tumors and viruses have developed many mechanisms to evade the immune
system, including down-regulation of target antigens and MHC molecules. These immune …

Introduction of a tumor antigen-specific T cell receptor (TCR) into patient-derived
lymphocytes has already exhibited promising results for the treatment of melanoma and …

Adoptive T cell therapy, involving the ex vivo selection and expansion of antigen-specific T
cell clones, provides a means of augmenting antigen-specific immunity without the in vivo …

Antigen-specific T cells represent a potential therapeutic avenue for a variety of conditions,
but current approaches for generating such cells for therapeutic purposes are limited. In this …

T-cell receptor (TCR) gene therapy enables for the rapid creation of antigen-specific T cells
from mice of any strain and represents a valuable tool for preclinical immunotherapy studies …

Adoptive T-cell therapy of cancer often fails due to the tumor cells' immune escape
mechanisms, like antigen loss or down-regulation. To anticipate immune escape by loss of a …

T‐cells specific for foreign (eg, viral) antigens can give rise to strong protective immune
responses, whereas self/tumor antigen‐specific T‐cells are thought to be less powerful …

The identification of appropriate mouse models could be useful in carefully evaluating the
actual role of the in vivo development of antigen‐loss variants during antigen‐specific …